Artwork

内容由touchpodcast提供。所有播客内容(包括剧集、图形和播客描述)均由 touchpodcast 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

52:36
 
分享
 

Manage episode 447191630 series 3389426
内容由touchpodcast提供。所有播客内容(包括剧集、图形和播客描述)均由 touchpodcast 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

touchCONGRESS for touchONCOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

  • Data reviews with Prof. Rosti
  • Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

  1. Approved and emerging TKIs for CML in the first-line setting
  2. Approved and emerging TKIs for CML in the second- and later-line settings
  3. Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

  • Prof. Gianantonio Rosti: Meldola, Italy
  • Prof. Susanne Saussele: Mannheim, Germany
  • Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: TBC

  continue reading

103集单集

Artwork
icon分享
 
Manage episode 447191630 series 3389426
内容由touchpodcast提供。所有播客内容(包括剧集、图形和播客描述)均由 touchpodcast 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

touchCONGRESS for touchONCOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

  • Data reviews with Prof. Rosti
  • Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

  1. Approved and emerging TKIs for CML in the first-line setting
  2. Approved and emerging TKIs for CML in the second- and later-line settings
  3. Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

  • Prof. Gianantonio Rosti: Meldola, Italy
  • Prof. Susanne Saussele: Mannheim, Germany
  • Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: TBC

  continue reading

103集单集

All episodes

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放